1-3 of 3
Sheila Shapouri, PharmD, MS
Close
Sort by
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019
Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4309.
https://doi.org/10.1182/blood-2019-128645
Published: 2019
Journal Articles

Nurse Treatment Preferences Survey for Intravenous Rituximab Infusion Versus Subcutaneous Rituximab Injection: A Real-World Study

Mitul D. Gandhi, MD, Sheila Shapouri, PharmD, MS, Arliene Ravelo, MPH, Lavanya Sudharshan, MS, Jamyia Clark, MPH, Keith L. Dawson, DNP, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5890.
https://doi.org/10.1182/blood-2019-123739
Published: 2019